Earnings ·
Reports Q3 net loss of $29.6M on $45.5M revenue and cuts FY26 outlook to $179.4-$200.0M
ORGOOrganogenesis Holdings Inc.
Organogenesis Holdings Inc. reported a third-quarter net loss of $29.6 million, or $(0.25) per share, compared to net income of $21.6 million in the prior-year period. Net revenue fell 70% year-over-year to $45.5 million, driven by a 73% decline in Advanced Wound Care sales. The company lowered its full-year 2026 revenue guidance to between $179.4 million and $200.0 million, reflecting a projected 65-68% decline from the previous year's total. As of September 30, 2026, the firm held $26.9 million in cash with no outstanding debt. Organogenesis Holdings Inc. operates in the regenerative medicine sector, developing and selling product solutions for advanced wound care and surgical markets.